Relay Therapeutics Management
Management criteria checks 3/4
Relay Therapeutics' CEO is Sanjiv Patel, appointed in Mar 2017, has a tenure of 7.08 years. total yearly compensation is $8.12M, comprised of 7.9% salary and 92.1% bonuses, including company stock and options. directly owns 1.04% of the company’s shares, worth $8.11M. The average tenure of the management team and the board of directors is 6 years and 4.7 years respectively.
Key information
Sanjiv Patel
Chief executive officer
US$8.1m
Total compensation
| CEO salary percentage | 7.9% |
| CEO tenure | 7.1yrs |
| CEO ownership | 1.0% |
| Management average tenure | 6yrs |
| Board average tenure | 4.7yrs |
Recent management updates
Recent updates
Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Just Trimmed Their Revenue Forecasts By 12%
Apr 17
Relay Therapeutics: Platform More Important Than Programs
Mar 13Relay Therapeutics: Tapping Into An Unmet Need At A High Price Tag
Feb 13Analyst Forecasts Just Became More Bearish On Relay Therapeutics, Inc. (NASDAQ:RLAY)
Jan 21We Think Relay Therapeutics (NASDAQ:RLAY) Can Afford To Drive Business Growth
Nov 14Will Relay Therapeutics (NASDAQ:RLAY) Spend Its Cash Wisely?
Jun 08Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?
Feb 22Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?
Oct 23Relay set to Equal Weight at Barclays; says fairly valued ahead of catalysts
Sep 30Relay Therapeutics: Bile Duct Cancer Approval Shot Validates Pricey Platform
Sep 18Why did Relay Therapeutics stock drop today?
Sep 09Estimating The Fair Value Of Relay Therapeutics, Inc. (NASDAQ:RLAY)
Jan 02Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Are Reducing Their Forecasts For This Year
Aug 17Relay Therapeutics, Inc. (NASDAQ:RLAY) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
May 16Relay Therapeutics (NASDAQ:RLAY) Is In A Strong Position To Grow Its Business
Mar 26Read This Before Selling Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares
Feb 01
Relay Therapeutics inks deal for RLY-1971 with Genentech
Dec 14Relay Therapeutics (NASDAQ:RLAY) Is In A Strong Position To Grow Its Business
Dec 08Relay Therapeutics reports Q3 results
Nov 12CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$342m |
| Sep 30 2023 | n/a | n/a | -US$326m |
| Jun 30 2023 | n/a | n/a | -US$344m |
| Mar 31 2023 | n/a | n/a | -US$323m |
| Dec 31 2022 | US$8m | US$642k | -US$291m |
| Sep 30 2022 | n/a | n/a | -US$290m |
| Jun 30 2022 | n/a | n/a | -US$267m |
| Mar 31 2022 | n/a | n/a | -US$384m |
| Dec 31 2021 | US$9m | US$603k | -US$364m |
| Sep 30 2021 | n/a | n/a | -US$261m |
| Jun 30 2021 | n/a | n/a | -US$414m |
| Mar 31 2021 | n/a | n/a | -US$247m |
| Dec 31 2020 | US$4m | US$585k | -US$230m |
| Sep 30 2020 | n/a | n/a | -US$289m |
| Jun 30 2020 | n/a | n/a | -US$95m |
| Mar 31 2020 | n/a | n/a | -US$86m |
| Dec 31 2019 | US$4m | US$585k | -US$75m |
Compensation vs Market: Sanjiv's total compensation ($USD8.12M) is above average for companies of similar size in the US market ($USD3.47M).
Compensation vs Earnings: Sanjiv's compensation has been consistent with company performance over the past year.
CEO
Sanjiv Patel (49 yo)
7.1yrs
Tenure
US$8,121,840
Compensation
Dr. Sanjiv K. Patel, M.A., M.D., M.B.A., MBBS, had been an Independent Director at Prothena Corporation plc since May 18, 2021 until July 1, 2023. He serves as Independent Director of ARYA Sciences Acquisi...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Independent Chairman | 9yrs | US$573.63k | 0.18% $ 1.4m | |
| CEO, President & Director | 7.1yrs | US$8.12m | 1.04% $ 8.1m | |
| Co-Founder & Director | no data | US$538.63k | 0.76% $ 5.9m | |
| Chief Financial Officer | 6yrs | US$2.46m | 0.023% $ 177.6k | |
| Chief Legal Officer & Secretary | 6.1yrs | US$2.46m | 0.023% $ 181.9k | |
| President of Research & Development | 6yrs | US$3.78m | 0.037% $ 288.9k | |
| Chief Corporate Development Officer | 2.3yrs | US$2.43m | 0.033% $ 260.8k | |
| Vice President of Corporate Development & Strategy | 6.8yrs | no data | no data | |
| Chief Scientific Officer of Late Research | no data | no data | no data | |
| Chief Medical Officer & Head of Precision Medicine | 4.4yrs | no data | no data | |
| Chief Pharmaceutical Development Officer | 5.3yrs | no data | no data | |
| Chief Scientific Officer of Early Research | no data | no data | no data |
6.0yrs
Average Tenure
50yo
Average Age
Experienced Management: RLAY's management team is seasoned and experienced (6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Independent Chairman | 9yrs | US$573.63k | 0.18% $ 1.4m | |
| CEO, President & Director | 7.1yrs | US$8.12m | 1.04% $ 8.1m | |
| Co-Founder & Director | 7.8yrs | US$538.63k | 0.76% $ 5.9m | |
| Independent Director | 4.8yrs | US$543.63k | 0.019% $ 148.8k | |
| Independent Director | 5.5yrs | US$546.13k | 0% $ 0 | |
| Member of Oncology Advisory Board | 4.1yrs | no data | no data | |
| Independent Director | 7.1yrs | US$541.13k | 0.030% $ 238.0k | |
| Member of Oncology Advisory Board | 4.1yrs | no data | no data | |
| Independent Director | 4.5yrs | US$548.63k | 0.019% $ 148.8k | |
| Member of Oncology Advisory Board | 4.1yrs | no data | no data | |
| Member of Oncology Advisory Board | 4.1yrs | no data | no data | |
| Member of Oncology Advisory Board | 4.1yrs | no data | no data |
4.7yrs
Average Tenure
61.5yo
Average Age
Experienced Board: RLAY's board of directors are considered experienced (4.7 years average tenure).